

RESEARCH ARTICLE

The proportion of loss to follow-up from antiretroviral therapy (ART) and its association with age among adolescents living with HIV in sub-Saharan Africa: A systematic review and meta-analysis

Cheru Tesema Leshargie, Daniel Demant, Sahai Burrowes, Jane Frawley

1 Department of Public Health, College of Health Science, Debre Markos University, Debre Markos, Ethiopia, 2 School of Public Health, Faculty of Health, University of Technology Sydney, Ultimo, Australia, 3 School of Public Health and Social Work, Faculty of Health, Queensland University of Technology, Brisbane, Australia, 4 Public Health Program, College of Education and Health Sciences, Touro University California, Vallejo, CA, United States of America

* chertesema@gmail.com

Abstract

Background

Human immunodeficiency virus (HIV) remains a global health threat, especially in developing countries. The successful scale-up of antiretroviral therapy (ART) programs to address this threat is hindered by a high proportion of patient loss to follow-up (LTFU). LTFU is associated with poor viral suppression and increased mortality. It is particularly acute among adolescents, who face unique adherence challenges. Although LTFU is a critical obstacle on the continuum of care for adolescents, few regional-level studies report the proportion of LTFU among adolescents receiving ART. Therefore, a systematic review and meta-analysis were conducted to estimate the pooled LTFU in ART programs among adolescents living with HIV in sub-Saharan Africa (SSA).

Methods

We searched five databases (PubMed, Embase (Elsevier), PsycINFO, CINAHL, and Scopus) for articles published between 2005 and 2020 and reference lists of included articles. The PRISMA guidelines for systematic reviews were followed. A standardised checklist to extract data was used. Descriptive summaries were presented using narrative tables and figures. Heterogeneity within the included studies was examined using the Cochrane Q test statistics and I² test. Random effect models were used to estimate the pooled prevalence of LTFU among ALHIV. We used Stata version 16 statistical software for our analysis.

Results

Twenty-nine eligible studies (n = 285,564) were included. An estimated 15.07% (95% CI: 11.07, 19.07) of ALHIV were LTFU. Older adolescents (15–19 years old) were 43% (AOR =
0.57, 95% CI: 0.37, 0.87) more likely to be LTFU than younger (10–14 years old) adolescents. We find an insignificant relationship between gender and LTFU (AOR = 0.95, 95% CI: 0.87, 1.03). A subgroup analysis found that regional differences in the proportion of adolescent LTFU were not statistically significant. The trend analysis indicates an increasing proportion of adolescent LTFU over time.

Conclusions and recommendations
The proportion of LTFU among HIV-positive adolescents in SSA seems higher than those reported in other regions. Older adolescents in the region are at an increased risk for LTFU than younger adolescents. These findings may help policymakers develop appropriate strategies to retain ALHIV in ART services. Such strategies could include community ART distribution points, appointment spacing, adherence clubs, continuous free access to ART, and community-based adherence support.

Background
The prevalence of human immunodeficiency virus (HIV) infection continues to rise among adolescents in low-and middle-income countries [1, 2], particularly in sub-Saharan Africa (SSA) [3, 4], where 70% of people living with HIV (PLHIV) reside [5, 6]. In 2018, over 1.6 million adolescents in SSA lived with HIV; 190,000 adolescents were newly diagnosed with HIV, and 33,000 adolescents died from AIDS-related illnesses in the same year [7]. A relatively large proportion of adolescents living with HIV (ALHIV) was found in SSA compared to other regions [3, 8]. This was due primarily to high numbers of perinatal infections [8–10], the early age of sexual initiation [4, 9], and the scale-up of paediatric antiretroviral therapy (ART), which has resulted in increasing numbers of children living with HIV who survive to adolescence [3].

A high proportion of lost-to-follow patients increasingly challenges this successful scale-up of ART programs [11]. HIV treatment with ART requires consistent, long-term engagement with the health care system [12]. This is challenging for all PLHIV but may be especially difficult for adolescents who experience higher rates of loss to follow up (LTFU) in HIV treatment programs than younger children and adults [13–16].

There are several reasons for the relatively high rates of LTFU among adolescents. Firstly, while there have been steady improvements in HIV care and support for children and adults, in many settings, there remains significant room for improving diagnosis and treatment services for adolescents specifically as well as a recognised need for targeted policies and treatment guidelines for this population [17–19]. Secondly, a lack of coordination between paediatric and adult services may make navigating the health care system challenging for adolescents transitioning from paediatric to adult care [20]. Thirdly, the cognitive development and sensitivity to peer pressure that characterize adolescence may affect HIV treatment outcomes. There is evidence that adolescents living with chronic medical conditions such as HIV/AIDS often endure heightened social isolation as a result [16, 21]. For example, adolescents may skip HIV medication prescriptions and be absent from health facilities to conceal their HIV status from their peers [22]. This peer pressure and isolation may lead to high-risk behaviour, including dropping out of HIV care [16].

Maintaining or improving retention (defined as a regular patient engagement with medical care at a health facility) in ART treatment services is a priority in HIV treatment policy and
practice [23]. Low retention often leads to poor health outcomes, drug resistance, treatment failure, and patients being LTFU [24]. This, in turn, harms the sustainability and effectiveness of national HIV control and treatment efforts [17, 18].

Worldwide studies have identified several sociodemographic, clinical, and lifestyle factors associated with LTFU among ALHIV. Cohort data from the Asia-Pacific, the Caribbean, and Central and South American regions [25] have found LTFU associated with gender, age, and rural settings. Data from Thailand [26] have indicated that age and malnutrition have a significant association with LTFU.

In SSA, there are limited data on the treatment outcomes (i.e., death, viral suppression, and LTFU) of adolescents living with HIV [27]. Studies are also considerably varied in the proportion of adolescent LTFU they report [14, 28, 29], with estimates ranging from as low as 1.6% in South Africa [30] to as high as 32% in Uganda [31]. Such variation in the estimated proportion of adolescents LTFU in treatment programs makes it difficult for decision-makers to assess the problem and to develop appropriate and effective clinical and policy strategies in response. To address this lack of clarity, the current systematic review and meta-analysis aimed to estimate the pooled proportion of LTFU from ART services and its association with age among ALHIV in SSA. It also conducts a sub-group analysis to report regional LTFU estimates. The results obtained from this review provide basic background information for program planners and decision-makers designing regional and national strategies to reduce LTFU among adolescents. Furthermore, our review results could be used as baseline information for planning and evaluating national, regional, and international LTFU prevention strategies.

Methods
We used the Preferred Reporting Items of Systematic Reviews and Meta-analysis (PRISMA) checklist (detailed in S1 File) to guide this systematic review. A systematic review and meta-analysis protocol was registered on the Prospero database (ID: CRD42020190193) [32].

Inclusion and exclusion criteria
The study’s geographic scope comprises all 46 African countries in SSA [33]. All observational primary, peer-reviewed, English-language studies conducted in SSA that reported the proportion of LTFU from routine ART follow-up services and reported data on adolescents (using the WHO definition of those 10–19 years of age) were eligible for inclusion [34]. Studies published between January 1, 2005, and June 30, 2020, were included, as 2005 marks the year that the Joint United Nations Programme on HIV/AIDS (UNAIDS) announced a shift from small ART projects with short-term horizons to long-term, comprehensive strategies to manage the increase of HIV infections in the SSA region [35].

Search strategy
The authors developed a search strategy (detailed in S2 File) cooperating with a specialist librarian at the University of Technology Sydney Library (UTS). Five databases were searched in June 2020: PubMed, Embase (Elsevier), PsycINFO, CINAHL, and Scopus. We also hand-searched the reference lists and citations of relevant studies identified from the database search. We searched for articles using Boolean operators and the following Medical Subject Headings (MeSH) terms:

Line 1: “Antiretroviral therapy” OR "antiretroviral therapy" OR “Antiretroviral drugs” OR "antiretroviral drugs" OR "ART" OR "AIDS drugs" OR "Anti-AIDS drugs" OR "Anti-HIV
drugs” AND "loss to follow-up” OR "lost to follow-up” OR "loss to follow up” OR "treatment outcome” OR "LTFU” AND
Line 2: "Teen” OR "youth” OR "child” OR "Adolescent” AND
Line 3: "HIV” OR "Human immunodeficiency virus” OR "Human immunodeficiency infection” OR "AIDS” OR "acquired immunodeficiency syndrome” AND
Line 4: "all SSA countries”

Outcome measure and definition of terms
The primary review outcome was the prevalence of LTFU from ART among ALHIV. The LTFU was defined as a patient who had missed three health facility visits or antiretroviral medication pick-ups [36–39] or had gone for more than 90 days without follow-up contact the last missed appointment and had not died or transferred out [39]. We directly extracted the total number of ALHIV and the number of adolescents LTFU from included studies. Then, the prevalence was computed by dividing the number of adolescents LTFU by the entire study population and multiplying by 100. The secondary analysis outcome was the effect of age on LTFU among ALHIV on ART follow-up.

Heterogeneity across studies
Heterogeneity among included study effects and the pooled effect across studies was computed using the non-parametric Cochrane Q test [40]. Heterogeneity across studies was measured using I-squared (I²) test statistics [40]. A univariate meta-regression was used to identify the sources of heterogeneity between included studies.

Articles screening and data extraction process
Fig 1 shows the PRISMA flow diagram for this systematic review. All search results (N = 14,408) were downloaded into the citation management software EndNote, version X° (Thomson Reuters, London). Duplications (n = 7,983) were removed, and the remaining references (n = 6,425) were imported into Covidence (Veritas Health Innovative 2019) [41] for title screening, abstract and full-text review, and quality assessment. The Covidence software removed a further 44 duplicates. We screened 6,381 studies’ titles and abstracts, removing 6,252 irrelevant studies. A full-text assessment of the remaining 129 studies was performed. Two full-text articles were obtained from the primary author through email requests. One article was obtained through the UTS library. Full-text screening excluded 100 articles due to population differences (n = 56), differences in outcome of the study (n = 42), absence of full-text (n = 1) and study setting differences (n = 1). The final sample for the systematic review consisted of 29 studies.

The first author (CTL) extracted data from the original articles using a pre-piloted data extraction format in Microsoft™ Excel. The extraction format contained the first author, year of publication, study area/country, study design, sample size, outcome/LTFU, and adjusted hazard ratio/ adjusted odds ratio with 95% confidence intervals (CI) and age. Data on factors associated with LTFU were also extracted. Authors DD and JF checked extracted data for consistency.

Quality assessment
We assessed the selected studies’ quality using the Newcastle Ottawa Scale (NOS), one of the most frequently used tools for evaluating the quality of observational studies in meta-analyses.
The NOS evaluates three quality parameters: selection, comparability, and outcome, using eight items to measure the extent to which the research study addresses the possibility of bias in its method, design, and analysis [42]. Articles with a score \( \geq \) 6 out of 10 were considered high quality (S3 and S4 Files). The first author (CLT) assessed the included studies’ methodological quality using the NOS assessment tool [43]. Author DD then conducted a second review. Inter-observer reliability was checked during regular project meetings to ensure consistency, with author JF resolving discrepancies between the two reviewers.

**Statistical analysis**

Extracted data was exported to Stata™ Version 16 for further analysis. A metan Stata command was used to compute the estimate of the pooled prevalence of LFTU. We used both funnel plot asymmetry and Egger rank correlation tests to check for the presence of publication bias. The funnel plot is a graphical visual representation of the trials plotted against their report effect size. The funnel plot visual inspection indicated asymmetry, which suggests publication bias (see Fig 2). The Egger rank correlation test was applied to assess publication bias with a p-value < 0.05 demonstrating the presence of significant publication bias [44]. The Egger
regression test results (p = 0.001) confirmed the publication bias in the studies under review. The DerSimonian and Laird method was used to produce a random-effects meta-analysis. A sensitivity analysis was performed to assess a study that influenced the overall pooled estimate (see Fig 3). Subgroup analyses were performed by geographical region and study design to minimise the observed random variation between the primary studies. Finally, the effect of adolescent age on LTFU was examined, and the result was described using Adjusted Odds Ratios (AOR). Effect sizes were presented as adjusted odds ratios (AOR) with 95% CIs. The meta-regression analysis considered the odds of LTFU among young adolescents (10–14 years old) compared with older adolescents (15–19 years old) who were in the reference (control) category.

Fig 2. Funnel plot of the meta-analysis used to show a visual description of publication bias.
https://doi.org/10.1371/journal.pone.0272906.g002

Fig 3. Sensitivity analysis of the pooled prevalence meta-analysis.
https://doi.org/10.1371/journal.pone.0272906.g003
Results

Characteristics of the included primary articles

Twenty-nine studies (see Table 1) were included in the systematic review, with a combined sample size of 285,564 adolescents who had initiated ART. The smallest sample size was 65 [13], which was obtained from a South African study. The largest sample size (129,405) was obtained from a study conducted in Rwanda [45]. The majority (n = 23, 79.3%) of the included studies were retrospective cohort studies/analyses [14, 16, 28, 30, 31, 46–63]. We also included three (10.3%) prospective cohort studies [15, 64, 65], one (3.4%) case-controlled study [66], one (3.4%) comparative cross-sectional study [67], and one (3.4%) [45] cross-sectional analysis.

Six studies [15, 16, 52, 59, 63, 64] were conducted in Zimbabwe; five [13, 14, 30, 48, 62] in South Africa; three [15, 31, 55] in Uganda; two in Kenya [50, 56] and Rwanda [45, 53] each, and one study was conducted in Ethiopia [28], Zambia [67], Malawi [66], Namibia [54], and Nigeria [57]. The remaining five (n = 5) studies took place in more than one sub-Saharan Africa country [46, 49, 51, 58, 60] (Table 1).

Quality assessment

Three authors (CT, DD, and JF) assessed the quality of included studies using the New Ottawa Scale (NOS). The NOS quality scores for the included studies ranged from five to nine, with a mean score of 7.52 (SD: 1.15). Based on the NOS, the majority, 26 (89.7%) of the included studies, had good quality. The remaining three (10.3%) included articles were rated "low", with scores below the cut-off point (Table 2).

Meta-analysis

The pooled estimated LTFU (see Fig 4) computed from the 29 included studies was 15.07% (95% CI: 11.07, 19.07). The lowest (1.6%) and highest (36%) proportions of LTFU reported were both found in studies conducted in South Africa [30, 48]. The second-highest proportion of LTFU (32%) was reported by a study conducted in Uganda in 2016 [68].

The Cochrane-Q test (p < 0.001) and I^2 test statistics (I^2 = 99.9%) indicated the existence of heterogeneity between the included studies. A random-effects model was applied to estimate the effect size of LTFU among adolescents living with HIV.

Subgroup analyses

We also conducted subgroup analyses by study design (see Fig 5) and SSA geographical regions (see Fig 6). The results of our subgroup analysis by study design suggested a similar proportion of LTFU across all study designs. The proportion of LTFU was 15.21% (95% CI 12.11, 18.31), for retrospective cohort studies; 15.11% (95% CI: 3.37, 26.86) for prospective cohort studies; and 13.66% (95% CI: 0.35, 27.66) for other study designs (i.e., comparative cross-sectional, case-control and cross-sectional) (see Fig 5).

In the subgroup analysis assessed by region; the proportion of adolescents LTFU was 12.98% (95% CI: 9.04, 16.92) for Southern African studies; 14.01% (3.66, 24.35) for East Africa; and 16.82% (13.37, 20.26) for West Africa and 21.48% (95% CI: 13.32, 29.69) for SSA-wide studies (see Fig 6).

Factors associated with LTFU

Eight of the included studies examined factors associated with LTFU using multivariable logistic regression. The factors that were considered in the studies are outlined in Table 3. The
Table 1. Descriptive summary of 29 studies included in the meta-analysis of LTFU among HIV-positive adolescents (10–19 years old) on ART in SSA.

| Author                     | Publication year | region                                   | Study design                     | Sample size | Event of LTFU (%) | Prevalence of LTFU (%) | Quality assessment |
|----------------------------|------------------|------------------------------------------|----------------------------------|-------------|-------------------|------------------------|-------------------|
| Bakanda et al. [47]        | 2011             | Uganda                                   | Retrospective cohort study       | 575         | 42                | 7.3                    | High (7)          |
| Arrive et al. [46]         | 2012             | West Africa (Cote d'Ivoire, Mali, and Senegal) | Retrospective cohort study       | 650         | 85                | 13.1                   | High (7)          |
| Bygrave et al. [15]        | 2012             | Zimbabwe                                 | Prospective cohort study         | 157         | 26                | 16.6                   | High (7)          |
| Nglazi et al. [13]         | 2012             | South Africa                             | Prospective cohort study         | 65          | 3                 | 4.6                    | High (7)          |
| Shroufi et al. [59]        | 2013             | Zimbabwe                                 | Retrospective cohort study       | 1,776       | 164               | 9.2                    | Low (5)           |
| Evans et al. [14]          | 2013             | South Africa                             | Retrospective cohort study       | 651         | 94                | 14.4                   | High (7)          |
| Merkel et al. [53]         | 2013             | Rwanda                                   | Retrospective cohort study       | 196         | 4                 | 2.0                    | High (7)          |
| Mary-Ann Davies et al. [51]| 2014             | Southern Africa (Malawi, South Africa, and Zimbabwe) | Retrospective cohort study       | 2,161       | 158               | 7.3                    | High (6)          |
| Ojikutu et al. [57]        | 2014             | Nigeria                                  | Retrospective cohort study       | 225         | 44                | 19.6                   | High (7)          |
| Nabukeera-Barungi et al. [55]| 2015           | Uganda                                   | Retrospective cohort study       | 156         | 7                 | 4.5                    | High (8)          |
| Nsanzimana et al. [45]     | 2015             | Rwanda                                   | Cross-sectional analysis         | 129,405     | 2,847             | 2.2                    | High (7)          |
| Matyanga et al. [52]       | 2016             | Zimbabwe                                 | Retrospective cohort study       | 110         | 28                | 25.5                   | High (7)          |
| Koech et al. [50]          | 2014             | Kenya                                    | Retrospective cohort study       | 14,840      | 3,478             | 23.4                   | High (8)          |
| Okoboi et al. [31]         | 2016             | Uganda                                   | Retrospective cohort study       | 1,228       | 393               | 32                     | High (9)          |
| Fwemba & Musonda et al. [67]| 2017            | Zambia                                   | Comparative cross-sectional      | 1,334       | 268               | 20.1                   | High (9)          |
| Kranzer et al. [16]        | 2017             | Zimbabwe                                 | Retrospective cohort study       | 1,260       | 167               | 13.3                   | High (9)          |
| MacKenzie et al. [66]      | 2017             | Malawi                                   | Case-control                     | 617         | 116               | 18.8                   | High (8)          |
| McHugh et al. [64]         | 2017             | Zimbabwe                                 | Prospective cohort study         | 385         | 92                | 24                     | High (7)          |
| Vogt et al. [63]           | 2017             | Zimbabwe                                 | Retrospective cohort study       | 1,260       | 167               | 13.3                   | High (6)          |
| Schomaker et al. [58]      | 2017             | Southern Africa and West Africa          | Retrospective cohort study       | 2,618       | 467               | 17.8                   | Low (5)           |
| Fatti et al. [48]          | 2018             | South Africa                             | Retrospective cohort study       | 6,706       | 2,414             | 36                     | High (7)          |
| Kariminia et al. [49]      | 2018             | Sub-Saharan Africa (Central, East, Southern, West) | Retrospective cohort study       | 35,494      | 8,448             | 23.8                   | High (8)          |
| Slogrove [60]              | 2018             | Low, middle, and upper-income sub-Saharan Africa country | Retrospective cohort study       | 90,888      | 10,725            | 11.8                   | High (7)          |
| Slogrove et al. [61]       | 2018             | Sub-Saharan Africa                       | Retrospective cohort study       | 30,168      | 3,982             | 13.2                   | High (8)          |
| Anderson et al. [30]       | 2019             | South Africa                             | Retrospective cohort study       | 127         | 2                 | 1.6                    | High (7)          |
| Jerene et al. [28]         | 2019             | Ethiopia                                 | Retrospective cohort study       | 816         | 138               | 16.9                   | High (7)          |
| Ngeno et al. [56]          | 2019             | Kenya                                    | Retrospective cohort study       | 710         | 168               | 23.7                   | High (8)          |
proportion of LTFU among adolescents was significantly correlated with age, time of ART initiation, disclosure status, CD4+ cell count, urban/rural residence, and baseline WHO stage. Younger ALHIV (10–14 years old) were 43% less likely to be LTFU (AOR = 0.57, 95% CI: 0.37, 0.87) compared to older adolescents (age 15–19 years old) [15, 16, 28, 49, 50, 52, 54, 67] (see Fig 7).

Not knowing one’s HIV status dramatically increased the odds of LTFU among adolescents (AOR = 23.7, 95% CI: 17.9, 30.8, \(p < 0.05\)) [14, 27, 56]. Late ART initiation was also significantly associated with an increase in the proportion of adolescents LTFU (AOR = 8.72, 95% CI: 5.85, 13.02, \(p < 0.05\)) [28, 30, 49, 50, 69–71]. Adolescents with lower baseline CD4+ cell counts were more likely to be LTFU than adolescents with higher baseline CD4+ cell counts (AOR = 0.12, 95% CI: 0.10, 0.15, \(p < 0.05\)) [25]. LTFU was significantly higher (AOR = 1.40, 95% CI: 1.13, 1.75, \(p < 0.05\)) among adolescents from rural areas than those from urban areas [25]. Finally, adolescents in WHO Clinical Stages III and IV experienced higher LTFU than those in Stages I and II (AOR = 2.51, 95% CI: 1.90–3.13, \(p < 0.05\)) [50, 70].

Eight [28, 30, 31, 48–50, 52, 59] of our included studies assessed the effect of gender on LTFU among ALHIV, but our analysis found no significant relationship between gender and LTFU in this population (AOR = 0.95, 95% CI: 0.87, 1.03) (Fig 8).

### Trend of LTFU

A time-trend analysis of LTFU among ALHIV in SSA was estimated from the studies for the 2005 to 2020 time period. The analysis indicated that the proportion of LTFU increased from 2011 to 2020 (see Fig 9).

### Discussion

This systematic review and meta-analysis aimed to estimate the overall proportion of LTFU among ALHIV and its associations with age. To our knowledge, this systematic review and meta-analysis are the first in this region, focusing on LTFU in this population. LTFU is one of the main threats to patient retention and may persist even after ART services’ scale-up [72].

---

**Table 2. Describe articles rated lower quality using Newcastle Ottawa Scale (NOS) rating scale.**

| Studies          | Description of the quality status of included studies categorised as poor quality                                                                 |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Ngglazle et al.  | • The response rate (i.e., the proportion of the study sample completing the study and providing outcome data) is inadequate.                 |
| Nsanzimana et al.| • The sample size is not determined using the recommended assumptions  
• The response rate (i.e., the proportion of the study sample completing the study and providing outcome data) is inadequate.  
• Quality management is not adequately described, no training for data collectors is given |
| Marry-Ann et al. | • Eligibility criteria are not clearly defined  
• Lack of description of the derivation of the exposed group  
• An exciting variable is not clearly defined                                                                 |
We estimate that the pooled proportion of LTFU among adolescents in SSA was 15.07% (95% CI: 11.07, 19.07). This estimated prevalence is higher than those found previously in Europe (6.1%), North America (8.9%), South and Southeast Asia (7.1%), South America and the Caribbean (4.8%) [61, 73], and India (9.2%) [73].

The differences between our LTFU estimate and those found in other regions may be due to more fragile healthcare systems and a higher proportion of the population being of lower socioeconomic status in SSA. ART services are usually offered free of charge in national treatment programs in SSA; however, financially disadvantaged patients may still face considerable difficulties accessing care due to transportation costs, income loss from time away from work,
and other logistical challenges [74–76]. In addition to patient-level reasons for high LTFU in SSA, it must be noted that high LTFU in ART programs is usually a symptom of more considerable health system weakness [77], specifically a lack of resources required to offer the support, counselling, and outreach needed for patient retention.

The subgroup analysis by study setting indicates that variation between SSA regions was not statistically significant. The analysis found that the proportion of LTFU from ART programs was 14.01% (95% CI: 3.66, 24.35) in East Africa, 16.82% (13.37, 20.26) in West Africa, 12.98% (9.04, 16.92) in Southern Africa, and 21.48% (13.32, 29.63) in other SSA regions. A similar socioeconomic environment might explain the statistical insignificance of the variation in the proportion of LTFU between SSA regions.

Table 3. Descriptive summary of 8 included studies on the factors associated with LTFU among HIV-positive adolescents between 2005 and 2020.

| Articles                  | Publication year | Study design               | Sample size | Prevalence of LTFU (%) | Adjusted confounder for predictors of lost to follow-up |
|---------------------------|------------------|----------------------------|-------------|------------------------|--------------------------------------------------------|
| Munyayi et al. [54]       | 2020             | Retrospective cohort study | 385         | 5.7                    | Sex, age, CD4 count, Hgb at ART initiation, WHO clinical staging, BMI, kg/m2 |
| Jerene et al. [28]        | 2019             | Retrospective cohort study | 816         | 16.9                   | Age group, residence, CD4 at ART initiation (count/ml), Hgb at ART initiation, sex |
| Kariminia et al. [49]     | 2018             | Retrospective cohort study | 35,494      | 23.8                   | Sex, age, CD4 count, cells/mm3, WHO clinical staging, BMI, kg/m2, TB at ART initiation, ART regimen at Initiation, HIV status disclosed |
| Kranzer et al. [16]       | 2017             | Retrospective cohort study | 1,260       | 13.3                   | Sex, baseline age, current age, and time on ART |
| Fwemba & Musonda [67]     | 2017             | Comparative cross-sectional | 1,334       | 20.1                   | Age, ART regimen, WHO Stage, Time on ARV (months), sex, Baseline CD4 count, cell/mm3, Baseline hemoglobin |
| Matyanga et al. [52]      | 2016             | Retrospective cohort study | 110         | 25.5                   | Baseline age, CD4 count, Sex, WHO clinical staging, BMI, kg/m2, TB at ART initiation, HIV status disclose, ART regimen at initiation |
| Koech et al. [50]         | 2014             | Retrospective cohort study | 14,840      | 23.4                   | Age, CD4 cell count, WHO clinical stage, sex |
| Bygrave et al. [15]       | 2012             | Prospective cohort study  | 157         | 16.6                   | Age, CD4 counts, sex, year of Initiation, Time on ART (days), |

https://doi.org/10.1371/journal.pone.0272906.t003
Our time trend analysis of LTFU among ALHIV in SSA between 2005 and 2020 showed a linear trend with LTFU increasing each successive year after 2011. This might be explained by improvements in the quality of ART programs’ record-keeping and data management systems.

**Fig 7.** Forest plot showing the association of age and LTFU in ART treatment.

https://doi.org/10.1371/journal.pone.0272906.g007

**Fig 8.** Forest plot showing the association of gender and LTFU in ART treatment.

https://doi.org/10.1371/journal.pone.0272906.g008
over time, potentially leading to a more accurate reporting of LTFU in this population [78]. However, more precise reporting could just as easily lead to decreasing LTFU as people formerly misclassified as LTFU are correctly accounted for [79]. Studies have found that poor data management and inaccurate case definitions account for about 36% of the treatment outcomes that are wrongly classified [79]. Changing definitions of LTFU over time and across different countries may also explain increasing levels of LTFU. For example, the recommendation that more than 180 days of non-contact be used as the definition for LTFU was only made in 2011 [80], but many current ART treatment guidelines still define LTFU as 90 days without contact [36–39]. However, if countries have increasingly adopted this more stringent definition, we would expect to see levels of LTFU falling over time, not increasing. Rather than record-keeping or definition changes, growing socioeconomic pressures and demographic changes may have made retention more difficult in the region. As the history of the pre-treatment HIV/AIDS pandemic fades for younger cohorts, attitudes about the virus and knowledge of treatment may also be changing [5].

The secondary objective of this study was to identify associations between LTFU and age in this population. We found that older adolescents had higher rates of LTFU. This age effect seems to be found consistently in low- and high-income settings. For example, a study conducted in India on the same population reported that age affected treatment outcomes such as LTFU [73], as did cohort data from the Asia-Pacific region, the Caribbean, and Central and South America [25]. However, at least one study conducted in Thailand [26] reported that LTFU was higher among younger ALHIV.

There are several reasons why older adolescents may experience more difficulties remaining in ART treatment programs than their younger peers. Firstly, as adolescents’ age increases, awareness about HIV stigma may also increase and negatively affect their willingness to use ART services or disclose their HIV status [81]. Secondly, in the later stage, 15–19 years of age, adolescents are increasingly sexually active, leading to apprehensions about inadvertent partner disclosure if seen receiving HIV care [82].

Poor rates of clinic retention among adolescents also suggest that health system barriers exist to full commitment to HIV care [83]. Adolescent perceptions towards HIV medications are one of the most frequently reported barriers [84, 85], followed by fear of stigma and
discrimination [86, 87]. This, along with reduced family supervision and transitions from pediatric to adult care, could further limit follow-up as adolescents age [88].

Employment may be another explanation for the LTFU difference by age that we observe. The transition into adulthood may be associated with greater family responsibility for some adolescents, increasing demands on time, and relegating personal health to a secondary priority [89, 90]. Financial pressure may also lead to migration searching for employment, necessitating changing ART treatment providers. There is convincing evidence that a significant proportion of patients categorised as LTFU in SSA may have remained on ART but transferred to a different ART centre due to migration or other work-related reasons [91, 92]. In sum, the fear of stigma and inadvertent disclosure, the need to transfer care from paediatric to adult settings, and the high labour mobility of older adolescents may make them particularly prone to changing facilities and, therefore, to LTFU misclassification.

**Study limitations and future research**

This systematic review and meta-analysis have limitations that should be considered in interpreting its findings. Firstly, the studies included in the review had different patient follow-up times, which could have resulted in the under- or over-estimation of the overall proportion of LTFU. Secondly, most of the studies included in this review had small sample sizes, which might have affected the proportion of LTFU reported in them. Another limitation of the studies we reviewed was a lack of reporting on critical contextual health system factors that might affect ART programs’ ability to follow up patients and deliver quality care, such as how long the program had been in operation or the quantity and training of program staff. A fourth limitation is that the review only included articles published in English, which may have led to the omission of studies from Francophone and Lusophone Africa. Some studies also consider older adolescents as adults in their report, making it difficult to consider the data.

Finally, most studies reviewed were conducted in only small parts of sub-Saharan African countries, most of which had well-established, mature national HIV/AIDS treatment programs. Therefore, the estimates of LTFU we found may not represent countries with newer, smaller HIV/AIDS treatment programs.

This study also has several strengths. These include a search strategy developed with a specialised librarian’s assistance, including articles from multiple databases and manuals (reference lists), electronic searches, and rigorous data abstraction and analysis.

The limitations related to the content of primary articles highlight the need for additional LTFU research with adolescent-specific outcomes, including interventional studies and qualitative research to explore treatment experience and reasons for LTFU.

**Policy implications**

Our findings suggest the need for more finely grained, age-based HIV treatment protocols and counselling guides in the region. Current HIV treatment guidelines use age categories that largely ignore the unique needs of adolescents living with HIV. Patients less than 15 years of age are treated as paediatric patients and those 15 years and above as adults [93]. The development of supplemental guidelines and programs for ALHIV would address this life stage’s unique needs. For example, particular interventions could address young people’s fears about confidentiality and embarrassment about discussing health concerns, particularly reproductive health concerns, which form a powerful barrier to accessing care [94, 95]. Health professionals may benefit from guidance to overcome some of the challenges of working with young people, including communication difficulties, time constraints, uncertainty about the medico-legal status of those under 18 years, and managing consultations with parents present [96].
In addition to HIV-specific and clinical interventions, adolescents may require complementary services such as comprehensive, youth-friendly, family planning services and linkages to social protection and employment services. Supportive environments may be crucial for engaging adolescents living with HIV in their care. Programs that incentivise in-person follow-up with in-kind or cash benefits could be compelling in this population and improve older adolescents’ retention. There is evidence that these incentives can improve patient retention and reduce LTFU in adults [97, 98]. Finally, we recommend further qualitative studies to explore the client experience and possible reasons for LTFU among adolescents and additional interventional studies that assess programs to reduce LTFU in this population.

Conclusions

This systematic review and meta-analysis revealed that LTFU among adolescents receiving ART in SSA is considerably higher than in other regions. Older adolescents in the region are at higher risk for LTFU than younger adolescents. Our results provide crucial baseline LTFU estimates that policymakers and stakeholders can use to evaluate services and treatment initiatives to improve HIV treatment retention.

Supporting information

S1 File. PRISMA checklist.
(DOCX)

S2 File. Searching strategy (Boolean operators and MeSH) terms).
(DOCX)

S3 File. Quality assessment.
(DOCX)

S4 File. Quality assessment detail.
(DOCX)

Acknowledgments

The authors would like to forward unreserved acknowledgment to Helen Chan, a senior library staff, for her assistance in developing search strategies.

Author Contributions

Conceptualization: Cheru Tesema Leshargie, Sahai Burrowes.

Data curation: Cheru Tesema Leshargie, Jane Frawley.

Formal analysis: Cheru Tesema Leshargie, Sahai Burrowes.

Investigation: Cheru Tesema Leshargie.

Methodology: Cheru Tesema Leshargie, Daniel Demant, Sahai Burrowes, Jane Frawley.

Project administration: Cheru Tesema Leshargie.

Resources: Cheru Tesema Leshargie, Sahai Burrowes.

Software: Cheru Tesema Leshargie, Sahai Burrowes, Jane Frawley.

Supervision: Daniel Demant, Sahai Burrowes, Jane Frawley.

Validation: Daniel Demant, Sahai Burrowes, Jane Frawley.
Visualization: Daniel Demant, Jane Frawley.

Writing – original draft: Cheru Tesema Leshargie, Sahai Burrowes.

Writing – review & editing: Cheru Tesema Leshargie, Daniel Demant, Sahai Burrowes, Jane Frawley.

References

1. HIV/AIDS JUNPo: Global Report: UNAIDS report on the global AIDS epidemic 2013. Geneva: UNAIDS; 2013. Google Scholar 2017.

2. Cruz MLS, Cardoso CA: Perinatally infected adolescents living with human immunodeficiency virus (perinatally human immunodeficiency virus). *World journal of virology* 2015, 4(3):277. https://doi.org/10.5501/wjv.v4.i3.277 PMID: 26279988

3. Slogrove AL, Sohn AH: The global epidemiology of adolescents living with HIV: time for more granular data to improve adolescent health outcomes. *Current Opinion in HIV and AIDS* 2018, 13(3):170. https://doi.org/10.1097/COH.0000000000000449 PMID: 29432227

4. Bekker LG, Johnson L, Wallace M, Hosek S: Building our youth for the future. *Journal of the International AIDS Society* 2015, 18:20027. https://doi.org/10.7448/IAS.18.2.20027 PMID: 25724512

5. Kharsany AB, Karim QA: HIV infection and AIDS in sub-Saharan Africa: current status, challenges and opportunities. *The open AIDS journal* 2016, 10:34. https://doi.org/10.2174/1874613601610010034 PMID: 27347270

6. HIV/AIDS JUNPo: The Gap Report ISBN: 978-92-9253-062-4.; 2014. Accessed Feb 2018.

7. UNICEF Data: Epidemiology of HIV and AIDS Among Adolescents: Current status, inequities, and data gaps. 2019.

8. World Health Organization: Health for the world’s adolescents: a second chance in the second decade Geneva, Switzerland 2014.

9. Sohn AH, Hazra R: Old problems for new providers: managing the postpediatric HIV generation. In.: Oxford University Press US, 2017.

10. Bhardwaj S, Carter B, Aarons GA, Chi BH: Implementation research for the prevention of mother-to-child HIV transmission in sub-Saharan Africa: existing evidence, current gaps, and new opportunities. *Current HIV/AIDS Reports* 2015, 12(2):246–255. https://doi.org/10.1007/s11904-015-0260-1 PMID: 25877252

11. Ryan R, Dowler B, Bruce S, Garnage S, Morris A: The wellbeing of international students in the city of Sydney. Report prepared for the City of Sydney. In. Edited by Institute for Public Policy and Governance UoTS; 2016.

12. UNAIDS: The Gap Report 2014

13. Nglazi MD, Kranzer K, Holele P, Kaplan R, Mark D, Jaspan H, et al: Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. *BMC infectious diseases* 2012, 12(1):21. https://doi.org/10.1186/1471-2334-12-21 PMID: 22273267

14. Evans D, Menezes C, Mahomed K, Macdonald P, Unliedt S, Levin L, et al.: Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa. *AIDS research and human retroviruses* 2013, 29(6):892–900. https://doi.org/10.1089/AID.2012.0215 PMID: 23373540

15. Bygrave H, Mtangirwa J, Ncube K, Ford N, Kranzer K, Munyaradzi D: Antiretroviral therapy outcomes among adolescents and youth in rural Zimbabwe. *PloS one* 2012, 7(12). https://doi.org/10.1371/journal.pone.0052856 PMID: 23285204

16. Kranzer K, Bradley J, Musaazi J, Nyathi M, Gunguwo H, Ndebele W, et al.: Loss to follow-up among children and adolescents growing up with HIV infection: age really matters. *Journal of the International AIDS Society* 2017, 20(1):21737. https://doi.org/10.7448/IAS.20.1.21737 PMID: 28715186

17. Wong VJ, Murray KR, Phelps BR, Vermund SH, McCarrer DR: Adolescents, young people, and the 90–90–90 goals: a call to improve HIV testing and linkage to treatment. *AIDS (London, England)* 2017, 31(Suppl 3):S191.

18. Zanoni BC, Mayer KH: The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities. *AIDS patient care and STDs* 2014, 28(3):128–135. https://doi.org/10.1089/apc.2013.0345 PMID: 24601734

19. Ethiopia H, Prevention A: Control Office (HAPCO) And Global AIDS Monitoring & Evaluation Team (GAMET): World Bank Global HIV/AIDS Program, HIV/AIDS IN ETHIOPIA—AN EPIDEMIOLOGICAL SYNTHESIS. Washington, DC: World Bank 2008.
20. FEDERAL MINISTRY OF HEALTH: NATIONAL GUIDELINES FOR COMPREHENSIVE HIV PREVENTION, CARE AND TREATMENT. Feb, 2017.

21. Valencia LS, Cromer BA: Sexual activity and other high-risk behaviors in adolescents with chronic illness: A review. Journal of pediatric and adolescent gynecology 2000, 13(2):53–64. https://doi.org/10.1016/s1083-3188(00)00004-8 PMID: 10869664

22. HIInfo.NIH.gov: HIV and Children and Adolescents. August 19, 2021

23. Ekouevi DK, Balestre E, Ba-Gomis FO, Eholie SP, Maiga M, Amani-Bosse C, et al.: Low retention of

24. Geng EH, Nash D, Kambugu A, Zhang Y, Braitstein P, Christopoulos KA, et al.: Retention in care

25. Kariminia A, Law M, Davies MA, Vinokoor M, Wools-Kaloustian K, Leroy V, et al.: Mortality and losses to follow-up among adolescents living with HIV in the Ie DEA global cohort collaboration. Journal of the International AIDS Society 2018, 21(12):e25215. https://doi.org/10.1002/jia2.25215 PMID: 30548817

26. Kawilapat S, Salvadori N, Ngo-Giang-Huong N, Decker L, Kanjanavanit S, Puangsombat A, et al.: Incidence and risk factors of loss to follow-up among HIV-infected children in an antiretroviral treatment program. PloS one 2019, 14(9):e0222082. https://doi.org/10.1371/journal.pone.0222082 PMID: 31527875

27. Jerene D, Abebe W, Taye K, Ruff A, Hallstrom I: Adolescents living with HIV are at higher risk of death and loss to follow up from care: Analysis of cohort data from eight health facilities in Ethiopia. PloS one 2019, 14(10):e0223655. https://doi.org/10.1371/journal.pone.0223655 PMID: 31622391

28. Jerene D, Abebe W, Taye K, Ruff A, Hallstrom I: Adolescents living with HIV are at higher risk of death and loss to follow up from care: Analysis of cohort data from eight health facilities in Ethiopia. PloS one 2019, 14(10). https://doi.org/10.1371/journal.pone.0223655 PMID: 31622391

29. Biru M, Hallström I, Lundqvist P, Jerene D: Rates and predictors of attrition among children on antiretroviral therapy in Ethiopia: a prospective cohort study. PloS one 2018, 13(2). https://doi.org/10.1371/journal.pone.0189777 PMID: 29408897

30. Anderson K, Muloia R, Davies MA: Treatment outcomes in perinatally infected hiv-positive adolescents and young adults after ≥10 year antiretroviral therapy. South African Medical Journal 2019, 109(1):27–34.

31. Okoboi S, Ssali L, Yansaneh AI, Bakanda C, Birungi J, Nantume S, et al.: Factors associated with long-term antiretroviral therapy attrition among adolescents in rural Uganda: a retrospective study. Journal of the International AIDS Society 2016, 19:20841. https://doi.org/10.7448/IAS.19.5.20841 PMID: 27443271

32. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. Bmj 2015, 349:g7647. https://doi.org/10.1136/bmj.g7647 PMID: 25555855

33. Forsythe DP, Coate RA, Pease K-K: The United Nations and changing world politics: Westview Press; 2013.

34. Rajan PRS, Nagalingam S, Arumugam B: Behavioral and Emotional Changes among Adolescent Population. Int J Sci Stud 2018, 6(7):131–134.

35. UNAIDS/WHO: Joint United Nations Programme on HIV/AIDS (UNAIDS) World Health Organization (WHO). UNAIDS/0519E(English original, December 2005) 2005.

36. Calmy A, Klement E, Teck R, Berman D, Pécoul B, Ferradini L: Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up. AIDS 2004, 18(18):2353–2360. PMID: 15622311

37. Wools-Kaloustian K, Kimaiyo S, Diero L, Makombe SD, Schouten EJ, Yiannoutsos CT, et al.: True outcomes for large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. Aids 2006, 20(1):41–48. https://doi.org/10.1097/01.aids.0000196177.65551.ea PMID: 16327318

38. Yu JK-L, Chen SC-C, Wang K-Y, Chang C-S, Makombe SD, Schouten EJ, et al.: True outcomes for patients on antiretroviral therapy who are “lost to follow-up” in Malawi. Bulletin of the world health organization 2007, 85:550–554. https://doi.org/10.2471/bt.06.037739 PMID: 17768504

39. Seifu W, Ali W, Meresa B: Predictors of loss to follow up among adult clients attending antiretroviral treatment at Karamara general hospital, Jigjiga town, Eastern Ethiopia, 2015: a retrospective cohort study. BMC infectious diseases 2018, 18(1):280. https://doi.org/10.1186/s12879-018-3188-4 PMID: 29914400
40. Rücker G, Schwarzer G, Carpenter JR, Schumacher M: Undue reliance on I 2 in assessing heterogeneity may mislead. BMC medical research methodology 2008, 8(1):79. https://doi.org/10.1186/1471-2288-8-79 PMID: 19036172

41. Innovation V: CoBidence systematic review software. Melbourne, Australia 2019.

42. Wells GA, Shea B, O'Connell Da, Peterson J, Welch V, Losos M, et al.: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In.: Oxford; 2000.

43. Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute 2011.

44. Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T: Meta-analysis of prevalence. J Epidemiol Community Health 2013, 67(11):974–978. https://doi.org/10.1136/jech-2013-203104 PMID: 23963506

45. Muls E, Cools I, Vrijens B, Lambert M, Verstraelen S, Van de Wiele R, et al.: Clinical outcomes of HIV-infected youth and young adolescents enrolled in HIV care in Kenya. AIDS 2014, 28(18):2729–2738. https://doi.org/10.1097/QAD.0000000000000473 PMID: 25493599

46. Arrivé E, Dicko F, Amghar H, Aka AE, Dior H, Bouah B, et al.: HIV status disclosure and retention in care in HIV-infected adolescents on antiretroviral therapy (ART) in West Africa. PLoS One 2012, 7(3):e33690. https://doi.org/10.1371/journal.pone.0033690 PMID: 22457782

47. Bakanda C, Birungi J, Mwesigwa R, Nachega JB, Chan K, Palmer A, et al.: Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: Findings from a nationally representative cohort in Uganda. PLoS One 2011, 6(4). https://doi.org/10.1371/journal.pone.0019261 PMID: 21559441

48. Fatti G, Jackson D, Goga AE, Shaikh N, Eley B, Nachega JB, et al.: The effectiveness and cost-effectiveness of community-based support for adolescents receiving antiretroviral treatment: An operational research study in South Africa. An: Journal of the International AIDS Society 2018, 21.

49. Kariminia A, Law M, Davies MA, Vinikoor M, Wools-Kaloustian K, Leroy V, et al.: Mortality and losses to follow-up among adolescents living with HIV in the IeDEA global cohort collaboration. Journal of the International AIDS Society 2018, 21(12). https://doi.org/10.1002/jia2.25215 PMID: 30548817

50. Koch E, Teasdale CA, Wang C, Fayorsey R, Alwar T, Mukui IN, et al.: Characteristics and outcomes of HIV-infected youth and young adolescents enrolled in HIV care in Kenya. AIDS 2014, 28(18):2729–2738. https://doi.org/10.1097/QAD.0000000000000473 PMID: 25493599

51. Davies Mary-Ann, Stinson Kathryn, Technau Karl, Phiri Sam, Rabie Helena, Wellington Maureen, et al.: Outcomes of perinatally HIV-infected adolescents on antiretroviral therapy in Southern Africa. Topics in Antiviral Medicine 2014, 22:487–488.

52. Matyanga CM, Takarinda KC, Owiti P, Mutasa-Apollo T, Mugurungi O, Buruwe L, et al.: Outcomes of antiretroviral therapy among younger versus older adolescents and adults in an urban clinic, Zimbabwe. Public Health Action 2016, 6(2):97–104. https://doi.org/10.5588/ph.15.0077 PMID: 27358802

53. Merkel E, Gupta N, Niyonzima A, Niyonsenga SP, Nahimana E, Stulac S, et al.: Clinical outcomes among HIV-positive adolescents attending an integrated and comprehensive adolescent-focused HIV care program in rural Rwanda. Journal of HIV/AIDS & Social Services 2013, 12(3–4):437–450.

54. Munyayi FK, van Wyk B: The effects of Teen Clubs on retention in HIV care among adolescents in Windhoek, Namibia. South Afr J HIV Med 2020, 21(1):1031. https://doi.org/10.4102/sajhivmed.v21i1.1031 PMID: 32158557

55. Nabukenya-Barungi N, Elyanu P, Asire B, Katureebe C, Mukadi O, Namusoke E, et al.: Adherence to antiretroviral therapy and retention in care for adolescents living with HIV from 10 districts in Uganda. BMC Infect Dis 2015, 15:520. https://doi.org/10.1186/s12879-015-1265-5 PMID: 26573923

56. Ngeno B, Waruru A, Inwani I, Nganga L, Wangari EN, Katana A, et al.: Disclosure and Clinical Outcomes Among Young Adolescents Living With HIV in Kenya. Journal of Adolescent Health 2019, 64 (2):242–249. https://doi.org/10.1016/j.jadohealth.2018.08.013 PMID: 30482659

57. Ojikutu B, Higgins-Biddle M, Greeson D, Phelps BR, Amzel A, Okechukwu E, et al.: The association between quality of HIV care, loss to follow-up and mortality in pediatric and adolescent patients receiving antiretroviral therapy in Nigeria. PLoS ONE 2014, 9(7). https://doi.org/10.1371/journal.pone.0100039 PMID: 25075742

58. Schomaker M, et al.: Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: A multiregional analysis from Southern Africa, West Africa and Europe International Journal of Epidemiology 2017, 46(2):453–465. https://doi.org/10.1093/ije/dyw097 PMID: 27342202

59. Shroufi A, Gungwu H, Dixon M, Nyathi M, Ndebele W, Saint-Sauveur JF, et al.: HIV-infected adolescents in southern Africa can achieve good treatment outcomes: results from a retrospective cohort study. Aids 2013, 27(12):1971–1978. https://doi.org/10.1097/QAD.0b013e32836149ea PMID: 23525033
60. Slogrove AL: Inequality in outcomes for adolescents living with perinatally acquired HIV in sub-Saharan Africa: A Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Cohort Collaboration analysis: A. Journal of the International AIDS Society 2018, 21.
61. Slogrove AL, Schomaker M, Davies M-A, Williams P, Balkan S, Ben-Farhat J, et al.: The epidemiology of adolescents living with perinatally acquired HIV: a cross-region global cohort analysis. PLoS medicine 2018, 15(3). https://doi.org/10.1371/journal.pmed.1002514 PMID: 29494593
62. Tsondai PR, Braithwaite K, Fatti G, Bolton Moore C, Chimbete C, Rabie H, et al.: Describing the characteristics and long-term outcomes of adolescents living with perinatally acquired HIV in the IeDEA-Southern Africa collaboration: 2004 to 2017. Journal of the International AIDS Society 2019, 22.
63. Vogt F, Rehman AM, Kranzer K, Nyathi M, Van Griensven J, Dixon M, et al.: Relationship between time to initiation of antiretroviral therapy and treatment outcomes: A cohort analysis of ART eligible adolescents in Zimbabwe. Journal of Acquired Immune Deficiency Syndromes 2017, 74(4):390–398. https://doi.org/10.1097/QAI.0000000000001274 PMID: 28002183
64. McHugh G, Simms V, Dauya E, Bandason T, Chonzi P, Metaxa D, et al.: Clinical outcomes in children and adolescents initiating antiretroviral therapy in decentralized healthcare settings in Zimbabwe. Journal of the International AIDS Society 2017, 20(1). https://doi.org/10.7448/IAS.20.1.21843 PMID: 28872269
65. Nkala B, Khuwane M, Dietrich J, Ot wombke K, Sekoane B, et al.: Kganya Motsha Adolescent Centre: A model for adolescent friendly HIV management and reproductive health for adolescents in Soweto, South Africa. AIDS Care 2015, 27(6):697–702. https://doi.org/10.1080/09540121.2014.993352 PMID: 23599113
66. MacKenzie RK, van Lettow M, Gondwe C, Nyirongo J, Singano V, Banda V, et al.: Greater retention in care among adolescents on antiretroviral treatment accessing “Teen Club” an adolescent-centred differentiated care model compared with standard of care: a nested case-control study at a tertiary referral hospital in Malawi. J Int AIDS Soc 2017, 20(3).
67. Fwemba I, Musonda P: Modelling adverse treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics in Lusaka. Public Health 2017, 147–8. https://doi.org/10.1016/j.puhe.2017.01.022 PMID: 28940402
68. Okoboi S, Ssali L, Yansaneh AI, Bakanda C, Birungi J, Nantume S, et al.: Factors associated with long-term antiretroviral therapy attrition among adolescents in rural Uganda: A retrospective study. Journal of the International AIDS Society 2016, 19. https://doi.org/10.7448/IAS.19.5.20841 PMID: 27443271
69. Bygrave H, Mtsangirwa J, Ncube K, Ford N, Kranzer K, Munyaradzi D: Antiretroviral therapy outcomes among adolescents and youth in rural Zimbabwe. PLoS One 2012, 7(12):e52856. https://doi.org/10.1371/journal.pone.0052856 PMID: 23285204
70. Evans D, Menezes C, Mahomed K, Macdonald P, Untiedt S, Levin L, et al.: Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa. AIDS Res Hum Retroviruses 2013, 29(6):892–900. https://doi.org/10.1089/AID.2012.0215 PMID: 23373540
71. Kranzer K, Bradley J, Musaazi J, Nyathi M, Gungwu H, Ndebele W, et al.: Loss to follow-up among children and adolescents growing up with HIV infection: Age really matters: Age. Journal of the International AIDS Society 2017, 20(1). https://doi.org/10.7448/IAS.20.1.21737 PMID: 28715158
72. Megerso A, Garoma S, Tolosa Elcha TW, Daba S, Tarekegn M, Habtamulu Z: Predictors of loss to follow-up in antiretroviral treatment for adult patients in the Oromia region, Ethiopia. HIV/AIDS (Auckland NZ) 2016, 8:83. https://doi.org/10.2147/HIV.S96137 PMID: 27175095
73. Nimkar S, Valvi C, Kadam D, Rewari B, Kinkar A, Gupte N, et al.: Loss to follow-up and mortality among HIV-infected adolescents receiving antiretroviral therapy in Pune, India. HIV medicine 2018, 19(6):395–402. https://doi.org/10.1111/hiv.12605 PMID: 29573312
74. Miller CM, Keithapile M, Rybascak-Smith H, Rosen S: Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Tropical Medicine & International Health 2010, 15:48–54. https://doi.org/10.1111/j.1365-3156.2010.02514.x PMID: 20586960
75. Maskew M, MacPhail P, Menezes C, Rubel D: Lost to follow-up—contributing factors and challenges in South African patients on antiretroviral therapy. South African medical journal 2007, 97(9):853–857. PMID: 17985056
76. Alizadeh F, Mtifumunoza G, Stephens J, Habimaana C, Myles K, Baganizi M, et al.: Identifying and reengaging patients lost to follow-up in rural Africa: the “horizontal” hospital-based approach in Uganda. Global Health: Science and Practice 2019, 7(1):103–115. https://doi.org/10.9745/GHSP-D-18-00394 PMID: 30926739
77. Tweya H, Obobo IK, Gugsa ST, Phiri S, Rambiki E, Banda R, et al.: Loss to follow-up before and after initiation of antiretroviral therapy in HIV facilities in Lilongwe, Malawi. PloS one 2018, 13(1):e0188488. https://doi.org/10.1371/journal.pone.0188488 PMID: 29373574
78. Organization WH: Data quality assessment of national and partner HIV treatment and patient monitoring data and systems: implementation tool. In.: World Health Organization; 2018.

79. Etooni D, Wringe A, Kabudula CW, Renju J, Rice B, Gomez-Olive FX, et al.: Misreporting of patient outcomes in the South African national HIV treatment database: consequences for programme planning, monitoring, and evaluation. Front Public Health 2020, 8:100. https://doi.org/10.3389/fpubh.2020.00100 PMID: 32318534

80. Chi BH, Yiannoutsos CT, Westfall AO, Newman JE, Zhou J, Cesar C, et al.: Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med 2011, 8(10):e1001111. https://doi.org/10.1371/journal.pmed.1001111 PMID: 22039357

81. Stangl AL, Lloyd JK, Brady LM, Holland CE, Baral S: A systematic review of interventions to reduce HIV-related stigma and discrimination from 2002 to 2013: how far have we come? Journal of the International AIDS Society 2013, 16:18734. https://doi.org/10.7448/IAS.16.18734 PMID: 24242268

82. Kurapati S, Vajpayee M, Raina M, Vishnubhatla S: Adolescents living with HIV: An indian profile. AIDS research and treatment 2012, 2012. https://doi.org/10.1155/2012/576149 PMID: 22778924

83. Ryscavage PA, Anderson EJ, Sutton SH, Reddy S, Taiwo B: Clinical outcomes of adolescents and young adults in adult HIV care. JAIDS Journal of Acquired Immune Deficiency Syndromes 2011, 58(2):193–197. https://doi.org/10.1097/QAI.0b013e31822d7564 PMID: 21826014

84. Corneli A, Vaz L, Dulyx J, Omba S, Rennie S, Behets F: The role of disclosure in relation to assent to participate in HIV-related research among HIV-infected youth: a formative study. Journal of the International AIDS Society 2009, 12(1):17. https://doi.org/10.1186/1758-2652-12-17 PMID: 19712468

85. Heeren GA, Jemmot III JB, Sidloyi L, Ngwan e Z, Tyler JC: Disclosure of HIV diagnosis to HIV-infected children in South Africa: focus groups for intervention development. Vulnerable children and youth studies 2012, 7(1):47–54. https://doi.org/10.1080/17450128.2012.656733 PMID: 22468145

86. Hogwood J, Campbell T, Butler S: I wish I could tell you but I can’t: Adolescents with perinatally acquired HIV and their dilemmas around self-disclosure. Clinical Child Psychology and Psychiatry 2013, 18(1):44–60. https://doi.org/10.1177/1359104511433195 PMID: 22287554

87. Hejoaka F: Care and secrecy: being a mother of children living with HIV in Burkina Faso. Social science & medicine 2009, 69(6):869–876. https://doi.org/10.1016/j.socscimed.2009.05.041 PMID: 19540644

88. Xu L, Munir K, Kanabkaew C, Le Coeur S: Factors influencing antiretroviral treatment suboptimal adherence among perinatally HIV-infected adolescents in Thailand. PloS one 2017, 12(2):e0172392. https://doi.org/10.1371/journal.pone.0172392 PMID: 28207891

89. Benson JE, Johnson MK: Adolescent family context and adult identity formation. Journal of Family Issues 2009, 30(9):1265–1286. https://doi.org/10.1177/0192513X09332967 PMID: 20161577

90. Kwon JA, Wickrama K: Linking family economic pressure and supportive parenting to adolescent health behaviors: Two developmental pathways leading to health promoting and health risk behaviors. Journal of Youth and Adolescence 2014, 43(7):1176–1190. https://doi.org/10.1007/s10964-013-0060-0 PMID: 24254978

91. Arnesen R, Moll AP, Shenoi SV: Predictors of loss to follow-up among patients on ART at a rural hospital in KwaZulu-Natal, South Africa. PLoS One 2017, 12(5):e0177168. https://doi.org/10.1371/journal.pone.0177168 PMID: 28542309

92. Fox MP, Bor J, Brennan AT, MacLeod WB, Maskew M, Stevens WS, Carmona S: Correction: Estimating retention in HIV care accounting for patient transfers: A national laboratory cohort study in South Africa. PLoS Medicine 2018, 15(8):e1002643. https://doi.org/10.1371/journal.pmed.1002643 PMID: 3096137

93. Droegoe KM, Muether PS, Hermann MM, Caramoy A, Viebahn U, Kirchhof B, et al.: Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefe’s Archive for Clinical and Experimental Ophthalmology 2013, 251(5):1281–1284. https://doi.org/10.1007/s00417-012-2177-3 PMID: 23086225

94. Booth ML, Bernard D, Quine S, Kang MS, Usherwood T, Alperstein G, et al.: Access to health care among Australian adolescents young people’s perspectives and their sociodemographic distribution. Journal of Adolescent Health 2004, 34(1):97–103. https://doi.org/10.1016/j.jadohealth.2003.06.011 PMID: 14706412

95. Ageyi WK, Mukiza-Gapere J, EPEMA EJ: Sexual behaviour, reproductive health and contraceptive use. Journal of Tropical Medicine and Hygiene 1994, 97:219–227. PMID: 8064944

96. Kang M, Bernard D, Booth M, Quine S, Alperstein G, Usherwood T, et al.: Access to primary health care for Australian young people: service provider perspectives. British Journal of General Practice 2003, 53(497):947–952. PMID: 14960219
97. Bower P, Brueton V, Gamble C, Treweek S, Smith CT, Young B, et al.: Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities. *Trials* 2014, 15(1):1–9. https://doi.org/10.1186/1745-6215-15-399 PMID: 25322807

98. Clouse K, Mongwenyana C, Musina M, Bokaba D, Long L, Maskew M, et al.: Acceptability and feasibility of a financial incentive intervention to improve retention in HIV care among pregnant women in Johannesburg, South Africa. *AIDS care* 2018, 30(4):453–460. https://doi.org/10.1080/09540121.2017.1394436 PMID: 29067861